Drugs / CTA30X UCAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05015972 | Aug 2021 → Jun 2023 | B-cell non-Hodgkin lymphoma | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTA30X UCAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05015972 ↗ |
| Modality | Cell therapy | “CTA30X UCAR-T is an allogeneic chimeric antigenreceptor T-cell (CAR-T) therapy” NCT05015972 ↗ |
| Route | Intravenous | “administered intravenously.” NCT05015972 ↗ |
| Target | CD19 | “targets CD19” NCT05015972 ↗ |